Bacterial Infection Probes and Imaging Strategies in Clinical Nuclear Medicine and Preclinical Molecular Imaging

被引:1
作者
Sasser, Todd A. [1 ,2 ]
Van Avermaete, Ashley E. [1 ]
White, Alexander [1 ]
Chapman, Sarah [4 ]
Johnson, James R. [3 ]
Van Avermaete, Tony [1 ]
Gammon, Seth T. [2 ]
Leevy, W. Matthew [1 ,4 ,5 ]
机构
[1] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA
[2] Carestream Hlth Mol Imaging, Woodbridge, CT 06525 USA
[3] Washington Univ, Sch Med, Dept Radiol, BRIGHT Inst Hlth,Mol Imaging Ctr, St Louis, MO 63110 USA
[4] Univ Notre Dame, Notre Dame Integrated Imaging Facil, Notre Dame, IN 46556 USA
[5] Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN 46556 USA
关键词
Bacterial infection; in vivo molecular imaging; nuclear medicine; probe development; INFRARED ZINC(II)-DIPICOLYLAMINE PROBE; POSITRON-EMISSION-TOMOGRAPHY; IN-VIVO; LABELED LEUKOCYTE; INFLAMMATION; RADIOPHARMACEUTICALS; FLUORESCENCE; ANTIBIOTICS; RECOGNITION; PEPTIDES;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
At present, a limited number of strategies exist for diagnostic imaging of patients with bacterial infection. While radiolabeled probes and white blood cells provide robust solutions to detect bacteria in humans, they also give false positives in cases of sterile inflammation. With the onset of bacterial drug resistance, and a clinical trend toward reducing the prescription of antibiotics, the need for highly specific infection detection protocols has been renewed. The preclinical research community has recently utilized new optical imaging strategies, alongside traditional radioimaging research, to develop novel infection probes with translational potential. Here we review the current clinical methods for imaging bacteria in humans, and discuss the efforts within the preclinical community to validate new strategies. The review of preclinical infection imaging probes is limited to those probes that could be feasibly adapted for use in humans with currently available clinical modalities.
引用
收藏
页码:479 / 487
页数:9
相关论文
共 48 条
  • [1] Akhtar M. S., 2012, INT J PEPT, DOI DOI 10.1155/2012/965238
  • [2] Optical properties of human skin, subcutaneous and mucous tissues in the wavelength range from 400 to 2000 nm
    Bashkatov, AN
    Genina, EA
    Kochubey, VI
    Tuchin, VV
    [J]. JOURNAL OF PHYSICS D-APPLIED PHYSICS, 2005, 38 (15) : 2543 - 2555
  • [3] Positron Emission Tomography as a Diagnostic Tool in Infection: Present Role and Future Possibilities
    Basu, Sandip
    Chryssikos, Timothy
    Moghadam-Kia, Siamak
    Zhuang, Hongming
    Torigian, Drew A.
    Alavi, Abass
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2009, 39 (01) : 36 - 51
  • [4] The use of technetium-99m radiolabeled human antimicrobial peptides for infection specific imaging
    Brouwer, C. P. J. M.
    Sarda-Mantel, L.
    Meulemans, A.
    Le Guludec, D.
    Welling, M. M.
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (10) : 1039 - 1052
  • [5] Receptor Binding Ligands to Image Infection
    Chianelli, M.
    Boerman, O. C.
    Malviya, G.
    Galli, F.
    Oyen, W. J. G.
    Signore, A.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (31) : 3316 - 3325
  • [6] Dams ETM, 2000, J NUCL MED, V41, P622
  • [7] Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases
    De Winter, F
    Vogelaers, D
    Gemmel, F
    Dierckx, RA
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (04) : 247 - 257
  • [8] Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms
    Ferro-Flores, Guillermina
    Ocampo-Garcia, Blanca E.
    Melendez-Alafort, Laura
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (08) : 1098 - 1106
  • [9] Future Diagnostic Agents
    Gemmel, Filip
    Dumarey, Nicolas
    Welling, Mick
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2009, 39 (01) : 11 - 26
  • [10] Clinically Proven Radiopharmaceuticals for Infection Imaging: Mechanisms and Applications
    Goldsmith, Stanley J.
    Vallabhajosula, Shankar
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2009, 39 (01) : 2 - 10